Search
Returning search results with filters:
Remove filter for
Audience: Healthcare
Remove filter for
Category: Drugs
Clear all
Search filters
Type
Audience
Category
Issue
Last updated
Recall class
Displaying 1 - 15 of 602 items.
Taisho Pharmaceutical Pabron Gold A (Granules) unlicensed product:, product is labelled to contain dihydrocodeine phosphate that is listed on Schedule I of the CDSA
RecallHealth product recall | 2024-06-10
PMS-PIRFENIDONE 267 & 801 mg: Data integrity concerns with products bioequivalence data that could lead to incorrect dosing.
RecallHealth product recall | 2024-06-07
Important Safety and Efficacy Information on ALBRIOZA (sodium phenylbutyrate and ursodoxicoltaurine) – Market Withdrawal and Continued Restricted Access
AlertHealth professional risk communication | 2024-06-07
Mint-Betahistine 8, 16 & 24mg: Data integrity concerns with product's bioequivalence data that could lead to incorrect dosing.
RecallHealth product recall | 2024-06-06
Accel-Ondansetron ODT 4 & 8 mg: Data integrity concerns with product's bioequivalence data that could lead to incorrect dosing.
RecallHealth product recall | 2024-06-06
Importation of USA-authorized Carbamazepine Extended-Release Tablets, USP 200 mg and 400 mg due to the current shortage of Canadian-authorized carbamazepine
AlertHealth professional risk communication | 2024-06-05
Jamp Digoxin tablet: Over-sized tablet
RecallHealth product recall | 2024-06-03
Sanis Health Duloxetine 60 mg Capsule; Exceeds acceptable interim intake limit for N-nitroso-duloxetine (NDLX)
RecallHealth product recall | 2024-05-16
Sandoz Fesoterodine Fumarate 8 mg tablet; Out-of-specification (diester impurity)
RecallHealth product recall | 2024-05-16
REDDY-SAPROPTERIN: Color change & decrease potency
RecallHealth product recall | 2024-05-03
Importation of Italian-authorized Cisatracurio Hikma 2 mg/mL Ampoules due to the Current Shortage of Canadian-authorized Cisatracurium Omega
AlertHealth professional risk communication | 2024-04-24
PMS-Duloxetine 60 mg: Exceeds acceptable interim intake limit for N-nitroso-duloxetine (NDLX)
RecallHealth product recall | 2024-04-17
PMS-Duloxetine 30 mg: Exceeds acceptable interim intake limit for N-nitroso-duloxetine (NDLX)
RecallHealth product recall | 2024-04-17
I-131 Diagnostic Capsule: Affected lots may have decreased thyroid uptake.
RecallHealth product recall | 2024-04-17
JAMP-Guanfacine XR 4 mg: Foreign matter
RecallHealth product recall | 2024-04-10